CALDARA, ALESSIA
CALDARA, ALESSIA
Dipartimento di Scienze Giuridiche Cesare Beccaria
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
2022 S. Cavalieri, M. Serena Serafini, A. Carenzo, S. Canevari, D. Lenoci, F. Pistore, R. Miceli, S. Vecchio, D. Ferrari, C. Moro, A. Sponghini, A. Caldara, M. Cossu Rocca, S. Secondino, G. Moretti, N. Denaro, F. Caponigro, E. Vaccher, G. Rinaldi, F. Ferraù, P. Bossi, L.F.L. Licitra, L. de cecco
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
2017 P. Bossi, R. Miceli, L..D. Locati, D. Ferrari, S. Vecchio, G. Moretti, N. Denaro, F. Caponigro, M. Airoldi, C. Moro, E. Vaccher, A. Sponghini, A. Caldara, S.G. Rinaldi, F. Ferrau, F. Nolè, S. Lo Vullo, F. Tettamanzi, L. Hollander, L.F.L. Licitra